Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Tumor Growth”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT00861471
What this trial is testing

Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer

Who this might be right for
Prostate CancerProstatic Neoplasms
NYU Langone Health 24
Not applicableLooking for participantsNCT06208397
What this trial is testing

MRE for Assessment of Histopathological Growth Patterns in Colorectal Liver Metastases

Who this might be right for
Metastatic Colorectal Cancer
Shengjing Hospital 50
Testing effectiveness (Phase 2)Looking for participantsNCT07157969
What this trial is testing

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

Who this might be right for
HCC - Hepatocellular Carcinoma
Peking Union Medical College Hospital 300
Large-scale testing (Phase 3)Looking for participantsNCT07185997
What this trial is testing

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

Who this might be right for
Non-Small-Cell Lung CancerMetastatic Non-Small-Cell Lung CancerAdvanced Non-Small-Cell Lung Cancer+3 more
ArriVent BioPharma, Inc.
Testing effectiveness (Phase 2)Study completedNCT00463788
What this trial is testing

Cetuximab and Cisplatin in the Treatment of "Triple Negative" (Estrogen Receptor [ER] Negative, Progesterone Receptor [PgR] Negative, and Human Epidermal Growth Factor Receptor 2 [HER2] Negative) Metastatic Breast Cancer

Who this might be right for
Breast Neoplasm
Merck KGaA, Darmstadt, Germany 181
Testing effectiveness (Phase 2)Study completedNCT05253807
What this trial is testing

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
Incyte Corporation 8
Large-scale testing (Phase 3)Study completedNCT00982111
What this trial is testing

First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin

Who this might be right for
Non Small Cell Lung Cancer
Eli Lilly and Company 633
Not applicableEnded earlyNCT01187381
What this trial is testing

An Observational Study of the Mean Duration of Trastuzumab (Herceptin) Treatment in Participants With Early or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 250
Early research (Phase 1)Study completedNCT00793975
What this trial is testing

Study of IMC-1121B in Patients With Tumors That Have Not Responded to Therapy

Who this might be right for
Advanced Solid Tumors
Eli Lilly and Company 37
Not applicableStudy completedNCT05132101
What this trial is testing

Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea

Who this might be right for
Metastatic Breast Cancer
Pfizer 2,758
Testing effectiveness (Phase 2)Study completedNCT01533181
What this trial is testing

Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer

Who this might be right for
Recurrent Small Cell Lung Carcinoma
National Cancer Institute (NCI) 44
Testing effectiveness (Phase 2)Looking for participantsNCT05498428
What this trial is testing

Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-small-Cell Lung
Janssen Research & Development, LLC 520
Large-scale testing (Phase 3)Study completedNCT00790400
What this trial is testing

Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)

Who this might be right for
Tuberous Sclerosis Complex (TSC)Lymphangioleiomyomatosis (LAM)
Novartis Pharmaceuticals 118
Testing effectiveness (Phase 2)WithdrawnNCT02747797
What this trial is testing

Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations

Who this might be right for
Advanced Cancer
Teresa Helsten, MD
Testing effectiveness (Phase 2)UnknownNCT05044988
What this trial is testing

HS-10342 in Chinese Patients With HR+/HER2- Advanced and/or Metastatic Breast Cancer

Who this might be right for
HR+/HER2- Advanced and/or Metastatic Breast Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 20
Large-scale testing (Phase 3)Study completedNCT00446225
What this trial is testing

Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer in Patients With Mutations in the TK Domain of EGFR

Who this might be right for
Non-Small Cell Lung Cancer
Spanish Lung Cancer Group 174
Testing effectiveness (Phase 2)WithdrawnNCT01479179
What this trial is testing

Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab

Who this might be right for
Breast Cancer
M.D. Anderson Cancer Center
Not applicableAvailableNCT06761976
What this trial is testing

Expanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 Mutation

Who this might be right for
Advanced Non-small Cell Lung CancerCancer
Bayer
Early research (Phase 1)Study completedNCT00356460
What this trial is testing

Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma

Who this might be right for
Carcinoma, Renal CellMelanoma
Genzyme, a Sanofi Company 29
Testing effectiveness (Phase 2)UnknownNCT04974879
What this trial is testing

Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Qingdao Central Hospital 20
Next Page
480